Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomePreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

TriSalus Life Sciences (TLSI) Net Income towards Common Stockholders (2022 - 2025)

TriSalus Life Sciences (TLSI) has 4 years of Net Income towards Common Stockholders data on record, last reported at -$9.8 million in Q4 2025.

  • For Q4 2025, Net Income towards Common Stockholders rose 10.45% year-over-year to -$9.8 million; the TTM value through Dec 2025 reached -$69.7 million, down 109.7%, while the annual FY2025 figure was -$69.7 million, 109.7% down from the prior year.
  • Net Income towards Common Stockholders reached -$9.8 million in Q4 2025 per TLSI's latest filing, up from -$39.8 million in the prior quarter.
  • Across five years, Net Income towards Common Stockholders topped out at $1.9 million in Q2 2022 and bottomed at -$54.7 million in Q4 2022.
  • Average Net Income towards Common Stockholders over 4 years is -$14.2 million, with a median of -$9.1 million recorded in 2023.
  • The widest YoY moves for Net Income towards Common Stockholders: up 79.15% in 2024, down 1885.42% in 2024.
  • A 4-year view of Net Income towards Common Stockholders shows it stood at -$54.7 million in 2022, then increased by 4.55% to -$52.2 million in 2023, then surged by 79.15% to -$10.9 million in 2024, then rose by 10.45% to -$9.8 million in 2025.
  • Per Business Quant database, its latest 3 readings for Net Income towards Common Stockholders were -$9.8 million in Q4 2025, -$39.8 million in Q3 2025, and -$9.0 million in Q2 2025.